Department of Urology, Medical College of Wisconsin, 9200 West Wisconsin Avenue, Milwaukee, WI 53226, USA.
Curr Opin Urol. 2011 Jan;21(1):22-6. doi: 10.1097/mou.0b013e32834100dd.
Therapeutic tools for classic benign prostate hyperplasia (BPH) have focused on the dynamic component of obstruction and/or elimination of the static component via surgical or pharmaceutical therapies. Unfortunately, an exact cause for this disease process has not been identified, but additional insight has been achieved. This article presents an update of the BPH literature with a special focus on basic science or translational studies concerned with the cause of clinically significant BPH with lower urinary tract symptoms (LUTS).
Investigators are exploring connections between BPH with clinically significant LUTS, the metabolic syndrome, inflammation, alterations in cell signaling, and genetics which in turn has provided additional information concerning the pathogenesis, medical therapies as well as surgical therapies.
BPH is a chronic, progressive disease with important care implications and financial risks to the healthcare system. Continued improvements in length of life will demand that we unlock the cause of LUTS secondary to BPH with the goal of prevention as the ideal therapy. Studies reported in the last year contributed to our understanding of the disease process and provide insight for additional studies.
经典良性前列腺增生症（BPH）的治疗工具主要集中在通过手术或药物治疗来解决梗阻的动力因素和/或消除静态因素。不幸的是，这种疾病的根本原因尚未确定，但已取得了更多的认识。本文介绍了 BPH 文献的更新，特别关注与具有下尿路症状（LUTS）的临床显著 BPH 病因相关的基础科学或转化研究。
研究人员正在探索具有临床显著 LUTS 的 BPH 与代谢综合征、炎症、细胞信号转导改变以及遗传学之间的联系，这反过来又为发病机制、医学治疗以及手术治疗提供了更多信息。
BPH 是一种慢性、进行性疾病，对医疗保健系统具有重要的护理意义和经济风险。随着预期寿命的延长，我们将需要揭示与 BPH 相关的 LUTS 的病因，以预防为理想的治疗方法。去年报道的研究有助于我们了解疾病的发展过程，并为进一步的研究提供了思路。
